HISTOMORPHOLOGICAL SPECTRUM AND IMMUNOHISTOCHEMICAL EXPRESSION OF S100 AND CD56 AMONG TUMORS OF PERIPHERAL NERVES-A CROSS-SECTIONAL STUDY

KARTHIK SIGAMANI; SHOBANA B; NAYANA CHANDRAN

doi:10.22159/ajpcr.2025v18i7.54673

Authors

KARTHIK SIGAMANI Department of Pathology, Karpaga Vinayaga Institute of Medical Sciences and Research Centre, Madhuranthagam, Tamil Nadu, India https://orcid.org/0000-0003-2268-9227
SHOBANA B Department of Pathology, Sree Balaji Medical College and Hospital, Chennai, Tamil Nadu, India https://orcid.org/0000-0003-4880-7279
NAYANA CHANDRAN Department of Pathology, Mount Zion Medical College, Adoor, Kerala, India. https://orcid.org/0009-0004-2089-6251

DOI:

https://doi.org/10.22159/ajpcr.2025v18i7.54673

Keywords:

Neurofibroma, Schwannoma, Malignant peripheral nerve sheath tumors, Immunohistochemistry

Abstract

Objectives: Peripheral nerve sheath tumors (PNSTs) encompass a range of distinct clinicopathological entities, from benign tumors such as schwannoma to high-grade malignant neoplasms known as malignant PNST (MPNST). Despite having classic, recognizable microscopic features, these neoplasms can occasionally be difficult to diagnose. Immunohistochemistry (IHC) using a panel of markers like S100 and CD56 is helpful in arriving at the correct diagnosis.

Methods: This was a cross-sectional study based on laboratory records. All the cases of peripheral nerve sheath tumors reported between January 2021 and December 2021 were retrieved and IHC using S100 and CD56 was carried out. The results were tabulated by scoring the intensity and extent of IHC staining.

Results: Neurofibromas and schwannomas did not differ significantly in terms of patient age or the anatomical sites of these tumors. CD56 was positive in the majority of neurofibromas (90%) compared to schwannomas (80%), whereas S100 was positive in all cases of schwannomas (100%) in comparison to neurofibromas (95%). There was a statistically significant difference in the staining intensity of CD56 more for neurofibromas (p=0.015) and that of S100 more for schwannomas (p=0.04).

Conclusion: CD56 and S100 IHC analysis will be a helpful supplementary tool for the histopathologist to distinguish peripheral nerve sheath tumors from other soft tissue tumors.

Downloads

Download data is not yet available.

References

Belakhoua SM, Rodriguez FJ. Diagnostic pathology of tumors of peripheral nerve. Neurosurgery. 2021;88(3):443-56. doi: 10.1093/ neuros/nyab021, PMID 33588442

Kar M, Deo SV, Shukla NK, Malik A, DattaGupta S, Mohanti BK, et al. Malignant peripheral nerve sheath tumors (MPNST)-clinicopathological study and treatment outcome of twenty-four cases. World J Surg Oncol. 2006;22:55.

Nonaka D, Chiriboga L, Rubin BP. SOX10: A pan-schwannian and melanocytic marker. Am J Surg Pathol. 2008;32(9):1291-8. doi: 10.1097/PAS.0b013e3181658c14, PMID 18636017

Fine SW, McClain SA, Li M. Immunohistochemical staining for calretinin is useful for differentiating schwannomas from neurofibromas. Am J Clin Pathol. 2004;122(4):552-9. doi: 10.1309/ AGBG-TBRJ-4W0B-C7LN, PMID 15487453

Mahmood AS, Abdullah BH, Museedi O, Hameedi AD, Dane S. Comparative clinicopathological and immunohistochemical study of oral schwannomas and neurofibromas. J Res Med Dent Sci. 2021;9:27-34.

Thway K, Fisher C. Malignant peripheral nerve sheath tumor: Pathology and genetics. Ann Diagn Pathol. 2014;18(2):109-16. doi: 10.1016/j. anndiagpath.2013.10.007, PMID 24418643

Guo A, Liu A, Wei L, Song X. Malignant peripheral nerve sheath tumors: differentiation patterns and immunohistochemical features - a mini-review and our new findings. J Cancer. 2012;3:303-9. doi: 10.7150/jca.4179, PMID 22773934

Karamchandani JR, Nielsen TO, Van De Rijn M, West RB. SOX10 and S100 in the diagnosis of soft-tissue neoplasms. Appl Immunohistochem Mol Morphol. 2012;20(5):445-50. doi: 10.1097/ PAI.0b013e318244ff4b, PMID 22495377

WHO Classification of Tumors Editorial Board. WHO Classification of Tumors of Soft Tissue and Bone tumors. 5th ed., Vol. 3. Lyon: International Agency for Research on Cancer; 2020. Available from: https://publications.iarc.fr/book-and-report-series/who-classification-of-tumours/soft-tissue-and-bone-tumours-2020

Naber U, Friedrich RE, Glatzel M, Mautner VF, Hagel C. Podoplanin and CD34 in peripheral nerve sheath tumors: Focus on neurofibromatosis 1-associated atypical neurofibroma. J Neurooncol. 2011;103(2):239-45. doi: 10.1007/s11060-010-0385-4, PMID 20821344

Dabbs DJ, editor. Diagnostic Immunohistochemistry: Theranostic and Genomic Applications. Philadelphia, PA: Elsevier Health Sciences; 2021.

Ghosh A, Talwar OP, Pradhan SV. Tumour and tumour-like conditions of peripheral nerve origin: Ten years’ experience. Kathmandu Univ Med J (KUMJ). 2010;8(29):97-101. doi: 10.3126/kumj.v8i1.3231, PMID 21209517

Perry A, Brat D, editors. Practical Surgical Neuropathology: A Diagnostic Approach. 1st ed. Philadelphia, PA: Churchill Livingstone, Elsevier; 2010. p. 620.

Danid NL, Hiroko O, Otmar DW. WHO classification of tumors-pathology and genetics of tumors of the nervous system. 4th ed. Switzerland: World Health Organization; 2007. p. 160.

Shivane A, Parkinson DB, Ammoun S, Hanemann CO. Expression of c-Jun and SOX-2 in human schwannomas and traumatic neuromas. Histopathology. 2013;62(4):651-6. doi: 10.1111/his.12062, PMID 23362975

Bellizzi AM. An algorithmic immunohistochemical approach to define tumor type and assign site of origin. Adv Anat Pathol. 2020;27(3):114-63. doi: 10.1097/PAP.0000000000000256, PMID 32205473

Do Nascimento GJ, De Albuquerque Pires Rocha D, Galvão HC, De Lisboa Lopes Costa A, De Souza LB. A 38-year review of oral schwannomas and neurofibromas in a Brazilian population: Clinical, histopathological and immunohistochemical study. Clin Oral Investig. 2011;15(3):329-35. doi: 10.1007/s00784-010-0389-7, PMID 20217161

Jaiswal P, Cd A, John JJ. A spectrum of histomorphological and immunohistochemical expression profiles of S-100, CD56 and calretinin in benign peripheral nerve sheath tumours. Cureus. 2023 Jun 21;15(6):e40751. doi: 10.7759/cureus.40751, PMID 37485115

Park JY, Park H, Park NJ, Park JS, Sung HJ, Lee SS. Use of calretinin, CD56, and CD34 for differential diagnosis of schwannoma and neurofibroma. J Pathol Transl Med. 2011;45(1):30-5. doi: 10.4132/ KoreanJPathol.2011.45.1.30

Gabhane SK, Kotwal MN, Bobhate SK. Morphological spectrum of peripheral nerve sheath tumors: A series of 126 cases. Indian J Pathol Microbiol. 2009 Jan-Mar;52(1):29-33. doi: 10.4103/0377-4929.44958, PMID 19136775

Rodriguez FJ, Folpe AL, Giannini C, Perry A. Pathology of peripheral nerve sheath tumors: Diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 2012;123(3):295-319. doi: 10.1007/s00401-012-0954-z, PMID 22327363

Oliveira FA, Fernandes CP, Mota MR, Sousa FB, Silva MR, Teófilo CR, et al. Expression of S-100, EMA, CD34 and presence of mast cells in eight oral neurofibromas, and a review of 127 cases of the literature. J Bras Patol Med Lab. 2013;49(5):347-54. doi: 10.1590/ S1676-24442013000500008

Patil SB, Chatura KR. Schwannoma and its unusual variants - a histopathological study. Indian J Pathol Oncol. Oct-Dec 2016;3(4): 727-31. doi: 10.5958/2394-6792.2016.00135.6

Kumari P, Panda P, Panigrahi R, Mishra PP. Schwannoma of the head and neck region: A case series in a tertiary health Centre in Western Odisha. Int J Curr Pharm Res. 2024 Mar;16(2):128-30. doi: 10.22159/ ijcpr.2024v16i2.4037

Guedes-Corrêa J, Cardoso R. Immunohistochemical markers for schwannomas, neurofibromas and malignant peripheral nerve sheath tumors-what can the recent literature tell us? Arq Bras Neurocir. 2018;37(2):105-12. doi: 10.1055/s-0038-1667180